On this page
Congenital fibre-type disproportion myopathy
CFTDM is a rare inherited muscle disorder that typically presents in infancy with generalised muscle weakness. It affects skeletal muscles, which are responsible for movement, and can impact motor development, breathing, and feeding.
Available at Jeen Health
Clinical tests that include this
Overview
Congenital fibre-type disproportion myopathy (CFTDM) is a rare genetic muscle disorder characterised by muscle weakness and hypotonia, meaning reduced muscle tone, usually apparent from birth or early infancy [PMID:22037748]. The condition gets its name from a specific finding observed in muscle biopsies: an unusual difference in the size of different types of muscle fibres. Specifically, the type 1 muscle fibres (involved in sustained activity) are typically smaller than type 2 fibres (involved in powerful, short bursts of activity), a pattern that is not observed in other congenital myopathies.
CFTDM affects the skeletal muscles throughout the body. The severity of the condition can vary widely between individuals, even within the same family. While some individuals may experience significant challenges with movement and breathing, others might have milder symptoms that improve over time. The condition is part of a group known as congenital myopathies, which are muscle disorders present at birth or shortly after.
Symptoms & clinical features
Individuals with CFTDM typically present with 'floppiness' or hypotonia at birth or in early infancy, along with general muscle weakness [PMID:22037748]. This weakness can affect various aspects of development and daily living. Common clinical features include delays in achieving motor milestones such as sitting, standing, and walking.
Respiratory issues can be a significant concern, with some babies experiencing breathing difficulties that may require support [PMID:32356230]. Feeding difficulties are also common, often due to weakness of the facial and swallowing muscles, which can lead to poor weight gain. Other features that may be seen include joint contractures (reduced range of motion in joints), scoliosis (a curvature of the spine), and in some cases, facial weakness. Intellectual development is typically unaffected in CFTDM.
Video: Genetics 101
Affected organs
CFTDM primarily affects the skeletal muscles, which are the muscles responsible for voluntary movement throughout the body. This includes muscles involved in maintaining posture, moving limbs, breathing, and swallowing. The heart muscle (cardiac muscle) is generally not directly affected by the primary muscle fibre disproportion, although some individuals may experience milder cardiac involvement in more severe forms of related myopathies. The brain and other internal organs are typically not directly impacted by CFTDM.
Risks & severity
The severity of CFTDM is highly variable, ranging from mild forms with gradual improvement to more severe presentations that can be life-threatening in infancy due to significant respiratory and feeding difficulties [PMID:22037748]. In some cases, muscle weakness and hypotonia may improve during childhood, leading to a more favourable long-term outcome. However, other individuals may experience persistent weakness, requiring ongoing support for mobility and daily activities.
Potential risks include respiratory failure, recurrent chest infections due to weak breathing muscles, and challenges with nutrition and growth. The overall prognosis is often related to the degree of respiratory involvement in early life. Long-term complications can include progressive scoliosis and joint contractures, which may need orthopaedic management.
Genetic causes
Congenital fibre-type disproportion myopathy is a genetic condition caused by pathogenic variants, or changes, in specific genes. Several genes have been identified as being associated with CFTDM. These include *ACTA1*, *RYR1*, *SELENON*, and *TPM3* [PMID:22037748]. These genes play crucial roles in maintaining the normal structure and function of skeletal muscle fibres.
For example, *ACTA1* provides instructions for making alpha-1 skeletal muscle actin, a protein essential for muscle contraction. Variants in *ACTA1* can disrupt this process. *RYR1* provides instructions for a protein called ryanodine receptor 1, which is important for regulating calcium release within muscle cells, a critical step for muscle contraction. *SELENON* is involved in protecting muscle cells from oxidative stress, and *TPM3* provides instructions for a protein called tropomyosin 3, which helps regulate muscle contraction by controlling the interaction between actin and myosin. Pathogenic changes in any of these genes can lead to the characteristic muscle fibre abnormalities seen in CFTDM.
- ACTA1 actin alpha 1, skeletal muscle
- RYR1 ryanodine receptor 1The RYR1 gene encodes ryanodine receptor 1, a protein critical for calcium release in skeletal muscle cells, playing a key role in muscle contraction and relaxation.
- SELENON selenoprotein NThe SELENON gene provides instructions for producing selenoprotein N, a protein important for muscle development and protecting cells from oxidative stress.
- TPM3 tropomyosin 3
Inheritance pattern
CFTDM can be inherited in either an autosomal dominant or an autosomal recessive pattern, depending on the specific gene involved.
In autosomal dominant inheritance, a person is affected if they inherit just one copy of the altered gene from either parent. This means that an affected parent has a 50% chance of passing the condition on to each of their children. In some dominant cases, the genetic change may occur spontaneously (a 'de novo' variant) in the affected individual, meaning it is not inherited from either parent.
In autosomal recessive inheritance, a person must inherit two copies of the altered gene - one from each parent - to develop the condition. Parents who each carry one copy of the altered gene are typically unaffected carriers. With each pregnancy, carrier parents have a 25% chance of having an affected child, a 50% chance of having a child who is an unaffected carrier, and a 25% chance of having a child who inherits two normal copies of the gene.
Diagnosis & testing
The diagnosis of CFTDM is typically suspected based on clinical findings such as early-onset muscle weakness and hypotonia. A muscle biopsy is often a key diagnostic step, revealing the characteristic disproportionately small type 1 muscle fibres compared to type 2 fibres [PMID:22037748].
Confirmation of CFTDM usually involves genetic testing, which can identify pathogenic variants in one of the associated genes (*ACTA1*, *RYR1*, *SELENON*, *TPM3*, among others). In the UK, genetic testing for inherited myopathies is available through the NHS Genomic Medicine Service (GMS) pathways. Referrals for genetic testing are typically made by a consultant paediatrician, neurologist, or clinical geneticist. These tests fall under specific R-codes within the GMS, allowing for comprehensive gene panel analysis. A clinical geneticist or genetic counsellor can provide further information and support regarding genetic testing options.
Management & lifestyle
While there is currently no cure for CFTDM, management focuses on supportive care to address symptoms and improve quality of life. Management is individualised and typically involves a multidisciplinary team of specialists, including paediatricians, neurologists, respiratory specialists, physiotherapists, occupational therapists, speech and language therapists, and dietitians.
Physiotherapy and occupational therapy are crucial for maintaining muscle strength, improving motor skills, and managing joint contractures. Respiratory support, such as non-invasive ventilation, may be needed for individuals with breathing difficulties [PMID:32356230]. Nutritional support, including tube feeding, might be necessary for those with significant feeding difficulties to ensure adequate growth and development. Regular monitoring for scoliosis and appropriate orthopaedic intervention, if needed, are also part of ongoing care. Genetic counselling is recommended for affected individuals and their families to understand the inheritance pattern and reproductive risks.
UK care pathway
In the UK, individuals with suspected or diagnosed genetic conditions like CFTDM are typically cared for within the NHS Genomic Medicine Service (GMS) framework. This pathway ensures access to specialist genetic testing through GMS Alliance laboratories, often initiated by a referral from a specialist clinician like a paediatrician, neurologist, or clinical geneticist. For CFTDM, relevant genetic tests fall under specific R-codes such as R47 (Neuromuscular disorders) or R21 (Congenital myasthenia and myopathy). Following diagnosis, ongoing care involves a multidisciplinary team. Access to genetic counselling services is a key part of the pathway, providing information and support to individuals and families.
Frequently asked questions
What does 'congenital' mean in this condition?
Congenital means that the condition is present from birth. In the case of CFTDM, muscle weakness and low muscle tone are typically noticed very early in an individual's life, often in infancy.
Will my child's muscle weakness improve?
The course of CFTDM can vary. Some individuals experience improvement in muscle strength and motor skills over time, sometimes leading to a milder outcome. Others may have persistent weakness. The specific genetic cause and severity of initial symptoms can influence the long-term outlook.
Can CFTDM be inherited from parents who do not have the condition themselves?
Yes, if CFTDM is inherited in an autosomal recessive pattern, both parents can be unaffected carriers of a changed gene. This means they each carry one copy of the gene variant but do not show symptoms. If both pass on their altered copy to their child, the child will develop the condition.
What kind of doctors will be involved in my child's care?
A team of specialists will generally be involved. This often includes a paediatrician, a neurologist specialising in muscle conditions, a respiratory specialist if breathing is affected, physiotherapists, occupational therapists, speech and language therapists, and dietitians. A clinical geneticist or genetic counsellor will also be part of the team.
Is there a cure for congenital fibre-type disproportion myopathy?
Currently, there is no cure for CFTDM. However, management focuses on supportive treatments and therapies to relieve symptoms, improve muscle function, manage associated health issues like breathing or feeding difficulties, and enhance the individual's quality of life. Research into new therapies is ongoing for genetic muscle conditions.
References
- Claeys KG. Congenital myopathies: an update. Developmental medicine and child neurology. 2020. PMID: 31578728
- Buisán F, de la Varga O, Flores M. Anaesthetic management of a paediatric patient with congenital fibre type disproportion myopathy. Revista espanola de anestesiologia y reanimacion. 2018. PMID: 29699707
- Cavanagh NP, Lake BD, McMeniman P. Congenital fibre type disproportion myopathy. A histological diagnosis with an uncertain clinical outlook. Archives of disease in childhood. 1979. PMID: 507896
- Young JA, Anderson JM. Infantile myopathy with type 1 fibre specific hypertrophy. Developmental medicine and child neurology. 1987. PMID: 3666331
- Sobreira C, Marques W Jr, Barreira AA. Myalgia as the revealing symptom of multicore disease and fibre type disproportion myopathy. Journal of neurology, neurosurgery, and psychiatry. 2003. PMID: 12933945